Update shared on 02 Nov 2025
Fair value Increased 5.74%Analysts have raised their price target for AlzChem Group from €154.24 to €163.10. They cite improved profit margin projections and continued confidence in the company's financial outlook.
What's in the News
- Alzchem Group AG and Ehrmann announce cooperation to launch new high-protein creatine products. These include puddings, drinks, and bars with Creavitalis®, available in stores from October 13, 2025 (Client Announcements).
- Creavitalis® ingredient will feature in the expanded "High Protein" line, delivering scientifically proven benefits for muscle strength and active lifestyles (Client Announcements).
- Staluna Trade A.S. and partners acquired a 9.71% stake in AlzChem Group AG from Löw SE, reducing Löw SE's ownership to 9.9% as of August 5, 2025 (M&A Transaction Closings).
Valuation Changes
- Fair Value: Increased from €154.24 to €163.10, reflecting a moderate upward adjustment.
- Discount Rate: Increased slightly from 5.21% to 5.25%.
- Revenue Growth: Marginally decreased from 9.45% to 9.35%.
- Net Profit Margin: Improved from 13.00% to 13.63%, indicating stronger profitability expectations.
- Future P/E: Decreased slightly from 16.74x to 16.67x.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.